Society for Endocrinology - a world-leading authority on hormones

News

Impressive increase in impact for Society's journals announced!

30 Jun 2021


The Society’s new journal impact factors have now been announced and they really are a cause for celebration, with impressive increases across the board!

Journal of Endocrinology's latest impact factor has increased to 4.286, with a solid increase in the five-year measure to 4.971. The journal now ranks 37th out of 143 journals in the endocrinology and metabolism category. 

The Journal of Molecular Endocrinology's impact factor has leapt up to 5.098, with the five-year measure also increasing to 4.755. It has now shot up 20 places in the endocrinology and metabolism category to be in the top quartile, cementing its position as one of the leading basic science journals dedicated to molecular endocrinology. 

Endocrine-Related Cancer has passed the five milestone and gone up to 5.678, with a five-year impact factor of 6.179. It now ranks 30 out of 143 journals in the endocrinology and metabolism category and 74 out of 242 in the oncology category.

Endocrine Connectionshas jumped to 3.335, with the five-year measure now standing at 3.489, giving it a ranking of 94 out of 145 journals in its category.

Clinical Endocrinology, our official clinical journal, published by Wiley, received an impact factor of 3.478, ranking 89 out of 145 journals.

All of our owned publications, Journal of Endocrinology, Journal of Molecular Endocrinology, Endocrine-Related Cancer and Endocrine Connections are published by our wholly-owned trading subsidiary, Bioscientifica, which redistributes all its profits back to the Society.

The Society for Endocrinology would like to thank the Editorial Boards, authors and reviewers for their tremendous hard work and dedication and all of our journal readers who use and cite articles. Together you ensure that the Society’s journals continue to be influential publications that help the Society to advance scientific and clinical education and research in endocrinology for the public benefit, one of its key aims.